NeuroVentures Capital is a venture capital firm founded in 2000 and based in Charlottesville, Virginia, claiming to be the largest U.S. See contact routes.
NeuroVentures Capital is a venture capital firm founded in 2000 and based in Charlottesville, Virginia, claiming to be the largest U.S. fund exclusively focused on neuroscience. The firm invests in companies developing drugs, medical devices, therapeutics, and technologies to treat central nervous system disorders such as stroke, chronic pain, epilepsy, Parkinson’s disease, and depression. It targets seed, Series A, and Series B stages, backing both development-stage and later-stage companies within the United States. NeuroVentures manages approximately $15 million and typically writes tickets ranging from $200,000 to $2 million. Notable portfolio companies include Acumen Pharmaceuticals (which IPO’d in July 2021), BrainCells Inc., EnVivo Pharmaceuticals, and Kadmus Pharmaceuticals. The firm builds concentrated positions across three pillars: neuro-pharmaceuticals, digital-therapeutic platforms for cognitive behavioral interventions, and neurotechnology hardware like non-invasive brain-stimulation devices. Its mandate explicitly excludes general healthcare services and biotech outside the central nervous system.
This profile is part of the StartupFundraising firm database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find comparable investors.
Investors like NeuroVentures Capital · Full investor directory · Investor access · Company funding database